CLK1 and neoplasm: Tam et al. reported that the CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression by inhibiting SRSF phosphorylation and disrupted spliceosome activity in gastrointestinal cancer [44].